Page 40 - Journal of Structural Heart Disease Volume 4, Issue 4

Meeting Abstracts
142
55. LEFT RECURRENT LARYNGEAL NERVE PALSY AFTER LEFT PULMONARY ARTERY STENT INSERTION
Seul Gi Cha, Seung Min Baek, Gi Beom Kim
Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Korea, Republic of
We report a 10-year-old boy with left recurrent laryngeal nerve palsy (LRLNP) after left pulmonary artery (LPA) stent insertion. He received device closure of patent ductus arteriosus (PDA) at 1 year old and was transferred to our hospital for LPA stenosis nine years after PDA device clo- sure. Echocardiography (Fig A,B) and computed tomogra- phy (Fig C) con rmed LPA stenosis owing to PDA device. Follow-up echocardiography showed aggravation of LPA stenosis. Lung perfusion scan using technetium-99m showed a decreased perfusion in the left lung (25%) com- pared to the right lung (75%). We, thus, performed a LPA stent insertion using EV3 stent 10 mm diameter-17mm length, under general anesthesia.
Post-interventionally,hoarsenessdeveloped.Laryngoscopy performed 1 month after intervention revealed hypo-mo- bile left vocal fold and electromyography performed at 2 months post-intervention showed that the left thyroaryte- noid muscle had no motor unit action potential except for brillation suggesting LRLNP. He still had di culty in mak- ing high tone voice at 1 year follow-up.
LRLNP after endovascular procedure is extremely rare. Including this case, only three cases of LRLNP after LPA stent insertion have been reported. A more careful inter- vention is suggested in patients with pulmonary artery hypoplasia not associated with congenital heart defect or those with a PDA device.
56. ADO II OFF LABEL USE IN THE CLOSURE OF VARIOUS CONGENITAL HEART DEFECTS:
Nazmi Narin, Ozge Pamukcu, Ali Baykan, Suleyman Sunkak, Aydin Tuncay, Gozdenur Erkan
Erciyes University, Kayseri, Turkey
Background: Devices may be used for special purposes di erent than their production purpose. For instance, Amplatzer Ductal Occluder is actually designed for duct closure and its usage for closing defects other than ductus are named as o -label. The aim of this study is to empha- size o -label use of device: not only for PDA and VSD but also for other various congenital heart defects.
Material Method: This study is designed retrospectively, performed by the evaluation catheterization records of patients in whom ADO II and ADO II-AS devices were used in Erciyes University Medical Faculty Children Hospital, Pediatric Cardiology Department between 2011 and 2018. Patients’ demographic criteria: age, weight at the time of procedure was gathered. The diagnosis, size of device, fol- low-up period and complications were also noted.
Results: From April 2011 to March 2018, a total of 121 patients underwent transcatheter closure by ADO II and 66 patients by ADO II AS. The number of PDA closure with ADO II was 48; with ADO II AS were 62. Rest of the pro- cedures were all o -label. Types of o -label procedures performed were: VSD closure, residual mitral cleft closure, Aorta-Right atrium tunnel closure, pulmonary arteriove- nous stula occlusion, aorta-pulmonary window closure, and occlusion of the artery feeding accessory lobe in scim- itar syndrome, Gerbode defect occlusion.
Conclusion: Up to our knowledge; this study includes the largest pediatric case series with various di erent
55. Figure 1.
Journal of Structural Heart Disease, August 2018
Volume 4, Issue 4:114-206